Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before Transcatheter Aortic Valve Implantation
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Bioimpedance analysis data
研究概览
简要总结
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
详细描述
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
盲法说明
Open
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Major patients (>18 years)
- •Men or women
- •Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
- •Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol
排除标准
- •Patient not affiliated to social security
- •Inability to understand the information consent letter
- •Not having signed informed consent
- •Has a mental or legal incapacitation and is unable to provide informed consent.
研究组 & 干预措施
Heart failure patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
干预措施: Assessment of sarcopenia prevalence (Diagnostic Test)
TAVI patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
干预措施: Assessment of sarcopenia prevalence (Diagnostic Test)
结局指标
主要结局
Bioimpedance analysis data
时间窗: at day 1
Fat-free mass and body fat mass will be combined to report BMI in Kg/m2
Short physical performance battery
时间窗: at day 1
Balance test, 4-min walking test, 5 times getting-up test
Handgrip test
时间窗: at day 1
次要结局
- Trans-thoracic echography(at day 1)
- complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L)(at day 1)
- NT-ProBNP in ng/L(at day 1)
- CRP in mg/L(at day 1)
- Blood draw for serum creatinine in umol/L(at day 1)
- platelets in Giga/L(at day 1)
- urea in mmol/L(at day 1)
- albumin in g/L(at day 1)
- Electrocardiogram(at day 1)